168 related articles for article (PubMed ID: 8092425)
1. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract.
Sabbah A; Hassoun S; Le Sellin J; André C; Sicard H
Allergy; 1994 May; 49(5):309-13. PubMed ID: 8092425
[TBL] [Abstract][Full Text] [Related]
2. [Sublingual specific immunotherapy for rhinoconjunctivitis caused by grass pollens].
Sabbah A; Lesellin J; Hassoun S; Sicard H; André C
Allerg Immunol (Paris); 1993 Jun; 25(6):241-7. PubMed ID: 8357473
[TBL] [Abstract][Full Text] [Related]
3. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization.
Vourdas D; Syrigou E; Potamianou P; Carat F; Batard T; André C; Papageorgiou PS
Allergy; 1998 Jul; 53(7):662-72. PubMed ID: 9700035
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
6. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study.
Leynadier F; Banoun L; Dollois B; Terrier P; Epstein M; Guinnepain MT; Firon D; Traube C; Fadel R; André C
Clin Exp Allergy; 2001 Jul; 31(7):988-96. PubMed ID: 11467988
[TBL] [Abstract][Full Text] [Related]
8. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis.
Pradalier A; Basset D; Claudel A; Couturier P; Wessel F; Galvain S; André C
Allergy; 1999 Aug; 54(8):819-28. PubMed ID: 10485385
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis.
Malling HJ; Montagut A; Melac M; Patriarca G; Panzner P; Seberova E; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):387-93. PubMed ID: 19134019
[TBL] [Abstract][Full Text] [Related]
10. Monoid sublingual immunotherapy.
Palma-Carlos AG; Santos AS; Branco-Ferreira M; Pregal AL; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2006 Mar; 38(3):87-9. PubMed ID: 16752693
[TBL] [Abstract][Full Text] [Related]
11. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study.
de Blay F; Barnig C; Kanny G; Purohit A; Leynadier F; Tunon de Lara JM; Chabane H; Guérin L;
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):453-61. PubMed ID: 18051216
[TBL] [Abstract][Full Text] [Related]
12. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy in pollen-induced seasonal rhinitis and conjunctivitis: a randomized controlled trial.
Mösges R; Brüning H; Hessler HJ; Götz G; Knaussmann HG
Acta Dermatovenerol Alp Pannonica Adriat; 2007 Dec; 16(4):143-8. PubMed ID: 18204744
[TBL] [Abstract][Full Text] [Related]
14. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis.
Clavel R; Bousquet J; André C
Allergy; 1998 May; 53(5):493-8. PubMed ID: 9636808
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
17. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
Serrano E; Wahn HU; Didier A; Bachert C
Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
[TBL] [Abstract][Full Text] [Related]
19. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.
Nelson H; Cartier S; Allen-Ramey F; Lawton S; Calderon MA
J Allergy Clin Immunol Pract; 2015; 3(2):256-266.e3. PubMed ID: 25609326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
